Katy Rezvani, Vice President and Head of Institute for Cell Therapy Discovery and Innovation at MD Anderson Cancer Center, shared a post on LinkedIn about a paper she and Alexander Biederstädt authored published on Cancer Cell:
“Excited to share our paper published in Cancer Cell, co-authored by Dr. Alexander Biederstädt, providing a comprehensive overview of engineered natural killer (NK) cells for cancer therapy. We discuss the evolution of the field, advances in CAR and TCR NK platforms, and emerging strategies to enhance persistence, trafficking, and anti-tumor activity. Many congratulations to Alex for his outstanding contribution to this work!”
Title: Engineered natural killer cells for cancer therapy
Authors: Alexander Biederstädt, Katayoun Rezvani
More posts featuring Katy Rezvani on OncoDaily.